4 news items
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
SYRS
14 May 24
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
SYRS
9 Apr 24
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
SYRS
27 Mar 24
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
SYRS
25 Mar 24
of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding Syros' clinical development plans, the progression
- Prev
- 1
- Next